(Q27863460)

Nature Reviews Drug Discovery

PubMed

PubMed publication ID

15 November 2016

0 references

0 references

Elisabeth E Bond

0 references

Arnold J Levine

series ordinal

0 references

Gareth L Bond

series ordinal

0 references

language of work or name

English

0 references

publication date

December 2008

0 references

published in

1 reference

0 references

0 references

979-87

0 references

cites work

p53, the cellular gatekeeper for growth and division

1 reference

Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide

21 April 2017

1 reference

Functions of the MDM2 oncoprotein

21 April 2017

1 reference

Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain

21 April 2017

1 reference

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 April 2017

1 reference

p53 regulates maternal reproduction through LIF

21 April 2017

1 reference

A common polymorphism acts as an intragenic modifier of mutant p53 behaviour

21 April 2017

1 reference

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer

21 April 2017

1 reference

Involvement of PIAS1 in the sumoylation of tumor suppressor p53

21 April 2017

1 reference

NMR structure of the N-terminal domain of SUMO ligase PIAS1 and its interaction with tumor suppressor p53 and A/T-rich DNA oligomers

21 April 2017

1 reference

Activation of p53 by protein inhibitor of activated Stat1 (PIAS1)

21 April 2017

1 reference

Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity

21 April 2017

1 reference

ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins

21 April 2017

1 reference

A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53 at Thr55

21 April 2017

1 reference

Cyclin G recruits PP2A to dephosphorylate Mdm2

21 April 2017

1 reference

Live or let die: the cell's response to p53

21 April 2017

1 reference

Transcriptional control of human p53-regulated genes

21 April 2017

1 reference

Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6

21 April 2017

1 reference

Restoration of p53 function leads to tumour regression in vivo

21 April 2017

1 reference

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

21 April 2017

1 reference

The NCI60 human tumour cell line anticancer drug screen

21 April 2017

1 reference

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

21 April 2017

1 reference

AMP-activated protein kinase induces a p53-dependent metabolic checkpoint

21 April 2017

1 reference

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

21 April 2017

1 reference

Shaping genetic alterations in human cancer: the p53 mutation paradigm

31 March 2020

1 reference

Crippling p53 activities via knock-in mutations in mouse models

31 March 2020

1 reference

What have animal models taught us about the p53 pathway?

31 March 2020

1 reference

Apoptosis: a link between cancer genetics and chemotherapy

31 March 2020

1 reference

p53: a guide to apoptosis

31 March 2020

1 reference

Control of apoptosis by p53.

31 March 2020

1 reference

Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis

31 March 2020

1 reference

INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53.

31 March 2020

1 reference

Dissecting p53 tumor suppressor functions in vivo

31 March 2020

1 reference

p53 status and the efficacy of cancer therapy in vivo

31 March 2020

1 reference

p53 therapy in a patient with Li-Fraumeni syndrome

31 March 2020

1 reference

Modeling the therapeutic efficacy of p53 restoration in tumors

31 March 2020

1 reference

Updates on p53: modulation of p53 degradation as a therapeutic approach

31 March 2020

1 reference

Importance of p53 for cancer onset and therapy

31 March 2020

1 reference

Reactivation of mutant p53: molecular mechanisms and therapeutic potential

31 March 2020

1 reference

Restoration of p53 to limit tumor growth

31 March 2020

1 reference

MDM2 is a central node in the p53 pathway: 12 years and counting

31 March 2020

1 reference

MDM2 inhibitors for cancer therapy

31 March 2020

1 reference

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

31 March 2020

1 reference

Adenovirus p53 gene therapy

31 March 2020

1 reference

Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers

31 March 2020

1 reference

Molecular basis for heterogeneity of the human p53 protein

31 March 2020

1 reference

Primary structure polymorphism at amino acid residue 72 of human p53.

31 March 2020

1 reference

A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans

31 March 2020

1 reference

Haplotype structure and selection of the MDM2 oncogene in humans

31 March 2020

1 reference

MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner

31 March 2020

1 reference

The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma.

31 March 2020

1 reference

Is p53 polymorphism maintained by natural selection?

31 March 2020

1 reference

p53: a new player in reproduction

31 March 2020

1 reference

The polyproline region of p53 is required to activate apoptosis but not growth arrest.

31 March 2020

1 reference

Two polymorphic variants of wild-type p53 differ biochemically and biologically

31 March 2020

1 reference

Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo

31 March 2020

1 reference

iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53.

31 March 2020

1 reference

The codon 72 polymorphic variants of p53 have markedly different apoptotic potential

31 March 2020

1 reference

p53 polymorphic variants at codon 72 exert different effects on cell cycle progression

31 March 2020

1 reference

p53 codon 72 genotype affects apoptosis by cytosine arabinoside in blood leukocytes

31 March 2020

1 reference

p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis

31 March 2020

1 reference

Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs

31 March 2020

1 reference

A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells

31 March 2020

1 reference

A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells

31 March 2020

1 reference

MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma

31 March 2020

1 reference

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia

31 March 2020

1 reference

Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs

31 March 2020

1 reference

Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription.

31 March 2020

1 reference

MDM2 promoter polymorphism and pancreatic cancer risk and prognosis

31 March 2020

1 reference

Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients

31 March 2020

1 reference

MDM2Polymorphism, Survival, and Histology in Early-Stage Non–Small-Cell Lung Cancer

31 March 2020

1 reference

MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.

31 March 2020

1 reference

MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation

31 March 2020

1 reference

Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer

31 March 2020

1 reference

SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a

31 March 2020

1 reference

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

31 March 2020

1 reference

Phosphorylation of p53 at serine 37 is important for transcriptional activity and regulation in response to DNA damage

31 March 2020

1 reference

Cyclin G1 associates with MDM2 and regulates accumulation and degradation of p53 protein.

31 March 2020

1 reference

Role for PP2A in ARF signaling to p53.

31 March 2020

1 reference

The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways

31 March 2020

1 reference

Construction of Permutation Tests

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2656

1 reference

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

1013821268

0 references

Fatcat ID

release_ouuy4wmpu5cu3b37epwgjcyrn4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ouuy4wmpu5cu3b37epwgjcyrn4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

19043449

1 reference

Consolidated OpenCitations Corpus – April 2017